Abingdon Health PLC Result of AGM (7695W)

TIDMABDX

RNS Number : 7695W

Abingdon Health PLC

24 December 2021

24 December 2021

Abingdon Health plc

("Abingdon" or "the Company")

Results of Annual General Meeting ("AGM")

York, U.K. 24 December 2021: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that all resolutions put to shareholders at the Company's AGM held today were duly approved.

Enquiries:

 
 Abingdon Health plc                                   www.abingdonhealth.com/investors/ 
 Chris Yates, Chief Executive Officer                                    Via Walbrook PR 
 Melanie Ross , Chief Financial Officer 
 Christopher Hand, Non-Executive Chairman 
 
 Singer Capital Markets (Sole Broker and                        Tel: [phone] 
  Nominated Adviser) 
 Shaun Dobson, Peter Steel, Alex Bond (Corporate 
  Finance) 
 Tom Salvesen (Corporate Broking) 
 
 Walbrook PR Limited                 Tel: [phone] or [e-mail] 
 Paul McManus / Phillip                       Mob: [phone] 
  Marriage                                                                           082 
 Alice Woodings                                                 Mob: [phone] 
 
 

About Abingdon Health

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx(R) , a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGDKQBKKBDDQBB

(END) Dow Jones Newswires

December 24, 2021 05:05 ET (10:05 GMT)